|
|
|
|
TEVETEN® (eprosartan mesylate) is indicated for the treatment of hypertension. TEVETEN® blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor found in many tissues (e.g., vascular smooth muscle, adrenal gland). TEVETEN® belongs to a class of antihypertensive drugs known as angiotensin receptor blockers (ARBs). USE IN PREGNANCY: When used in pregnancy during the second and third trimesters, drugs that act directly on the renin angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, TEVETEN® and TEVETEN® HCT should be discontinued as soon as possible. Please see Prescribing Information, including WARNINGS: Fetal/Neonatal Morbidity and Mortality. For important information about TEVETEN®, please see Prescribing Information or visit the TEVETEN® website. Product information on this page is intended for U.S. health practitioners only. Patients and Canadian health practitioners should return to the User Profile Selection page and select accordingly.
If you have medical information questions or need to report an adverse event or product complaint, please contact the Biovail Medical Communications Center at 1-866-BIOVAIL (246-8245), option 3 by phone, or (908) 927-1850 by fax, or Email Med.Comm@BIOVAIL.com |
|
|
|||||||||||||||
|
|
|
|
|||||||||||||||||
| © 2007 Biovail Corporation - All Rights Reserved (BIO113B0602) | Privacy Policy | Disclaimers |
